Supernus Pharmaceuticals Q4 2023 Adj EPS $0.39 Misses $0.55 Estimate, Sales $164.31M Beat $155.03M Estimate
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 2023 adjusted EPS of $0.39, missing the $0.55 estimate, but sales of $164.31M exceeded the $155.03M estimate, a 1.80% decrease from the previous year.
February 27, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Supernus Pharmaceuticals reported lower-than-expected Q4 2023 adjusted EPS but exceeded sales estimates, with a slight decrease in sales compared to last year.
The mixed earnings report from Supernus Pharmaceuticals, with a miss on EPS but a beat on sales, presents a neutral outlook. The slight decrease in sales YOY indicates potential challenges but also resilience in revenue generation. The impact on the stock price is likely to be neutral in the short term as investors weigh the EPS miss against the sales beat.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100